Lantheus (NASDAQ:LNTH) Issues Q2 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its second quarter earnings guidance on Thursday. The company provided EPS guidance of $1.81-1.86 for the period, compared to the consensus EPS estimate of $1.66. The company issued revenue guidance of $380-390 million, compared to the consensus revenue estimate of $356.88 million. Lantheus also updated its FY24 guidance to $7.00-7.20 EPS.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. JMP Securities reaffirmed a market outperform rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. B. Riley lifted their price objective on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research note on Thursday, April 18th. StockNews.com raised Lantheus from a hold rating to a buy rating in a research note on Saturday, January 13th. Finally, Truist Financial reaffirmed a buy rating and issued a $82.00 price objective (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $104.71.

Lantheus Price Performance

LNTH stock opened at $74.60 on Thursday. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus has a 52-week low of $50.20 and a 52-week high of $100.85. The stock’s 50 day moving average is $62.22 and its two-hundred day moving average is $62.69. The company has a market capitalization of $5.11 billion, a PE ratio of 14.52 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Analysts predict that Lantheus will post 5.96 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 94,545 shares of company stock worth $6,169,936. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.